Skip to main content

Fina Biosolutions has been issued European patent No. 3099800

By November 2, 2020News

Andrew Lees, Ph.D.

Scientific Director at Fina BioSolutions LLC and Owner, Fina BioSolutions LLC

Fina Biosolutions has been issued European patent No. 3099800, Expression and Purification of CRM Proteins and Related Proteins, and Protein Domains. The patent covers expression of the conjugate vaccine carrier protein CRM197 in our E. coli strain engineered to have an oxidative cytoplasm. FinaBio markets the E. coli expressed CRM197 under the name EcoCRM®.

 

{iframe}https://www.linkedin.com/posts/andrew-lees-ph-d-a76a423_crm197-finabio-ecocrm-activity-6727746401045884928-TNaA/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.